HighTower Advisors LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 7.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 112,608 shares of the biopharmaceutical company’s stock after purchasing an additional 7,563 shares during the quarter. HighTower Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $27,785,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Wellington Management Group LLP increased its holdings in Alnylam Pharmaceuticals by 9.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after buying an additional 174,482 shares during the period. Legal & General Group Plc acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Alnylam Pharmaceuticals by 7.4% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock valued at $219,104,000 after acquiring an additional 50,329 shares during the period. Bank of New York Mellon Corp bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $148,128,000. Finally, Dimensional Fund Advisors LP increased its stake in Alnylam Pharmaceuticals by 27.3% in the first quarter. Dimensional Fund Advisors LP now owns 384,205 shares of the biopharmaceutical company’s stock valued at $127,071,000 after acquiring an additional 82,340 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.
Analyst Upgrades and Downgrades
ALNY has been the subject of a number of analyst reports. Needham & Company LLC cut their price target on shares of Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating for the company in a research note on Thursday, October 29th. TD Cowen lowered their price objective on Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Jefferies Financial Group increased their target price on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a report on Tuesday, September 8th. Wells Fargo & Company dropped their target price on Alnylam Pharmaceuticals from $253.00 to $220.00 and set an “equal weight” rating for the company in a report on Friday, October 30th. Finally, Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $287.70.
Read Our Latest Analysis on ALNY
Recent Alnylam Pharmaceuticals Headlines
Investors following ALNY have been watching these headlines:
- Positive Sentiment: Regeneron received FDA approval for Livsayis (cemdisiran), a treatment for myasthenia gravis developed with Alnylam. Alnylam is due a $25 million approval payment and is also eligible for royalties; the company described it as the seventh FDA-approved therapy from its RNAi platform in less than nine years. Article: Alnylam to receive $25 million payment from Regeneron
- Positive Sentiment: BMO Capital Markets raised its price target slightly, to $293 from $292, and maintained an “outperform” rating. Article: BMO Capital Markets recommendations
- Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Alnylam investors. The notice is an investigation announcement, not a finding of wrongdoing. Article: Pomerantz investigates claims on behalf of Alnylam investors
Insider Activity at Alnylam Pharmaceuticals
In other news, EVP Bryan Supran sold 1,758 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company’s stock.
Alnylam Pharmaceuticals Price Performance
Shares of ALNY stock opened at $143.82 on Friday. The stock’s fifty day moving average is $208.79 and its 200-day moving average is $271.16. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. The stock has a market capitalization of $19.26 billion, a PE ratio of 7.47 and a beta of 0.42. Alnylam Pharmaceuticals, Inc. has a 52 week low of $143.40 and a 52 week high of $479.79.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the previous year, the business posted $2.90 earnings per share. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
Featured Articles
- Five stocks we like better than Alnylam Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
